Fight Aging! Newsletter, October 5th 2026
Key claim: Fight Aging! reports that PD-L1 blockade in the brain restores measures of glial cell function and argues that mTOR should not be treated as a single pharmaceutical target because biological context matters.
Abstract
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe to the newsletter, please visit: https://www.fightaging.org/newsletter/. To unsubscribe, send email or reply to this email at newsletter@fightaging.org with “unsubscribe” in the subject or body. Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out more: https://www.fightaging.org/services/ Contents PD-L1 Blockade in the Brain Restores Measures of Glial Cell Function Don’t View mTOR as a Single Pharmaceutical Target, as Context Matters A […]
Why this matters
Fight Aging! reports that PD-L1 blockade in the brain restores measures of glial cell function and argues that mTOR should not be treated as a single pharmaceutical target because biological context matters.